These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 8077792)

  • 21. [Raynaud's phenomenon and anticentromere antibodies].
    Marquet Palomer R; Vilardell Tarrés M; Ordi Ros J
    Med Clin (Barc); 1987 Nov; 89(17):721-4. PubMed ID: 3501051
    [No Abstract]   [Full Text] [Related]  

  • 22. [Minimal work-up for Raynaud syndrome: a consensus report. Microcirculation working group of the Société française de médecine vasculaire].
    Pistorius MA; Carpentier PH;
    Ann Dermatol Venereol; 2013; 140(8-9):549-54. PubMed ID: 24034643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Raynaud's phenomenone: prospective study of 100 cases (author's transl)].
    Vayssairat M; Fiessinger JN; Housset E
    Nouv Presse Med; 1979 Jun; 8(26):2177-80. PubMed ID: 471766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Raynaud's phenomenon and connective tissue diseases].
    Guilmot JL; Diot E; Lasfargues G; Boissier C
    Rev Prat; 1998 Oct; 48(15):1647-52. PubMed ID: 9814065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Etiological profile of secondary Raynaud's phenomenon in an internal medicine department. About 121 patients].
    Ben Salem T; Tougorti M; Bziouech S; Lamloum M; Khanfir M; Ben Ghorbel I; Houman MH
    J Med Vasc; 2018 Feb; 43(1):29-35. PubMed ID: 29425538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Raynaud's phenomena: diagnostic and treatment study].
    Priollet P
    Rev Prat; 1998 Oct; 48(15):1659-64. PubMed ID: 9814067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How to classify Raynaud's phenomenon. Long-term follow-up study of 73 cases.
    Priollet P; Vayssairat M; Housset E
    Am J Med; 1987 Sep; 83(3):494-8. PubMed ID: 3661586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The 'distal-dorsal difference': a thermographic parameter by which to differentiate between primary and secondary Raynaud's phenomenon.
    Anderson ME; Moore TL; Lunt M; Herrick AL
    Rheumatology (Oxford); 2007 Mar; 46(3):533-8. PubMed ID: 17018538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Major clinical diagnoses found among patients with Raynaud phenomenon from the general population.
    Maricq HR; McGregor AR; Diat F; Smith EA; Maxwell DB; LeRoy EC; Weinrich MC
    J Rheumatol; 1990 Sep; 17(9):1171-6. PubMed ID: 2290157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Secondary Raynaud's phenomenon].
    Röther E; Galle J; Peter HH
    Immun Infekt; 1993 Jun; 21(3):59-63. PubMed ID: 8392969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The usefulness of power Doppler ultrasonography in differentiating primary and secondary Raynaud's phenomenon.
    Lee SI; Lee SY; Yoo WH
    Clin Rheumatol; 2006 Nov; 25(6):814-8. PubMed ID: 16391889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Sarpogrelate hydrochloride for Raynaud's phenomenon of patients with collagen diseases].
    Kumagai S; Morinobu A; Ozaki S; Nakao K; Ishida H
    Ryumachi; 1998 Jun; 38(3):504-10. PubMed ID: 9721558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Minimal etiological evaluation of Raynaud's phenomenon. 102 cases].
    Priollet P; Yeni P; Vayssairat M; Segond P; Tallon F; Housset E
    Presse Med; 1985 Nov; 14(39):1999-2003. PubMed ID: 2933722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic model based on nailfold capillaroscopy for identifying Raynaud's phenomenon patients at high risk for the development of a scleroderma spectrum disorder: PRINCE (prognostic index for nailfold capillaroscopic examination).
    Ingegnoli F; Boracchi P; Gualtierotti R; Lubatti C; Meani L; Zahalkova L; Zeni S; Fantini F
    Arthritis Rheum; 2008 Jul; 58(7):2174-82. PubMed ID: 18576359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cold stimulus fingertip lacticemy test--an effective method to monitor acute therapeutic intervention on primary Raynaud's phenomenon and systemic sclerosis.
    Fontenelle SM; Kayser C; Pucinelli ML; Andrade LE
    Rheumatology (Oxford); 2008 Jan; 47(1):80-3. PubMed ID: 18077495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thumb involvement in Raynaud's phenomenon as an indicator of underlying connective tissue disease.
    Chikura B; Moore T; Manning J; Vail A; Herrick AL
    J Rheumatol; 2010 Apr; 37(4):783-6. PubMed ID: 20194444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Raynaud's phenomenon and systemic diseases: immunological viewpoint].
    Lantin JP; Duc J
    Rev Med Suisse Romande; 1992 May; 112(5):401-4. PubMed ID: 1604100
    [No Abstract]   [Full Text] [Related]  

  • 38. [Raynaud's phenomenon].
    Sprynger M
    Rev Med Liege; 2004 Jun; 59(6):378-84. PubMed ID: 15346976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The incidence and natural history of Raynaud's phenomenon in the community.
    Suter LG; Murabito JM; Felson DT; Fraenkel L
    Arthritis Rheum; 2005 Apr; 52(4):1259-63. PubMed ID: 15818710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis.
    Cutolo M; Sulli A; Pizzorni C; Accardo S
    J Rheumatol; 2000 Jan; 27(1):155-60. PubMed ID: 10648032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.